創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/11/15 GEM129 Immuno-modulator Anogenital warts, Actinic keratosis, Basal cell carcinoma Topical Small molecule
Phase 2 · The first product on the market that combines the therapeutic benefits of a marketed immunomodulator with an innovative transparent bioadhesive film.
· When applied to the lesion, generates a transparent bioadhesive film, which acts as a reservoir or matrix release and reduces the local reactions and increases the permanence of the product in the action site. · The results of non-clinical studies demonstrate that GEM129 has a better safety profile with an equivalent efficacy than its reference product. Clinical studies on-going.
問合せ
19/11/15 GEM128 Antibiotic Primary and secondary skin infection - canine pyoderma Topical Small molecule
Clinical for animal · The first medicine on the market that combines the therapeutic benefits of a marketed antibiotic with an innovative film-forming, long-lasting delivery technology.
· When applied to the lesion, generates a transparent film that acts as a bioadhesive sustained release matrix maintaining the optimum concentration of the antibiotic in the skin for a period of 6-8 hours. · The bioadhesive film generated reduces product removal from the area due to animal scratching, licking or friction with skin folds which contribute in improving the treatment efficacy. Also, reduces oral antibiotic overusing by improving topical treatment with this innovative technology. *Canine bacterial infections of the skin, including superficial pyoderma
問合せ
19/11/15 GEM127 Antibiotic Refer to Note Topical Small molecule
Launched Indication:
Primary and secondary skin infection - Impetigo, folliculitis, furunculosis (human use)

Note:
· The first product on the market that combines the therapeutic benefits of a marketed antibiotic with an innovative transparent film-forming and bioadhesive delivery technology.
· When applied to the lesion, generates a film that acts as a bioadhesive sustained release matrix, maintaining the optimum concentration of antibiotic in the skin for a period of 6-8 hours. · The bioadhesive film generated prevents the removal of the antibiotic from the lesion and acts as a protective dressing that prevents infection spreading.
問合せ
19/11/05 GEM126 Selective estrogen receptor downregulator ER+ advanced or metastatic breast cancer Oral Small molecule Phase 1 • Both antagonizes and degrades ER alpha in cells to achieve the goal of blocking the estrogen signaling pathway.
• Favorable oral pharmacokinetics in healthy rats and dogs whereas fulvestrant has a low bioavailability and can only be intramuscularly administrated.
• Favorable preclinical in vitro and vivo single agent efficacy in inhibiting ER+ breast cancer cell proliferation, in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer.
• Highly selective, no effect on other kinases and receptors.
• Can be licensed to global area with some limitation
問合せ
19/11/05 GEM124 Improves endothelial cell function and cellular fluidity. Antiatherosclerotic, antiinflammatory, anti-fibrotic, fat-targeting composition 1) Atherosclerosis (#) 2) Treatment of NASH (Stage F2-F3) Fibrosis with no worsening of fibrosis Oral Small molecules Preclinical 1) Developed to target vulnerable, high risk plaques while also reducing LDL cholesterol, increasing HDL cholesterol and reducing Triglycerides. (#) Future indications: primary prevention of Heart Attack, Stroke and Death and Secondary Prevention of Myocardial Infarction in Europe. US Patent to treat Atheroslersis is valid until 2035.
2) Concurrently being developed to treat liver inflammation, fibrosis and fat accumulation while also reducing LDL cholestrol and Triglycerides. *May be used in combination with other drugs, such as Intercept's Ocaliva that increases Triglycerides or Gilead's NASH candidate that increses LDL cholesterol.
問合せ
19/10/29 GEM123 miRNA targeting cancer stem cells colon cancer i.v. Nucleic acid
Preclinical GEM123 suppressed the stemness of cancer cells by inhibiting KLF5 expression, and provoked apoptosis and cycle arrest through the downregulation of TFDP1and MDM2 expressions.
GEM123 also inhibited tumor growth with no apparent side effect in mouse model.
問合せ
19/10/29 GEM122 Natural Killer T (NKT) cell-mediated anti-tumor responses Solid cancer i.v. Cell Therapy
Phase 1 GEM122 shows its anti-tumor activity by activating endogenous NKT cells.
Activated NKT cells strongly enhance both innate and acquired immune systems, induce the long-term immune memory and promote accumulation of TILs (tumor infiltrating lymphocytes) in tumor sites.
GEM122 consists of a novel NKT ligand and a novel APC.
The novel NKT ligand shows much stronger NKT activity than the previous NKT ligand, α-Galactosylceramide and by using the novel APC, the cellular product can be manufactured efficiently as well.
問合せ
19/10/23 GEM121 Modified phytic acid (inositol hexaphosphate: IP6) Cancer Oral Small molecule
Preclinical · Demonstrated selective anti-cancer effects including apoptosis and inhibition of Akt activation.
· In vivo study using mice with adult T-cell leukemia showed reduction of the size of the cancer.
問合せ
19/10/23 GEM120 Inhibition of membrane binding of Pr55Gag HIV i.v. Small molecule
Preclinical · Inhibited the membrane localization of Pr55Gag and stopped budding of HIV virus.
· Captures HIV in immune cells and induces apoptosis of the HIV-infected immune cells.
問合せ
19/10/23 GEM119 Inactivation of end-product of lipid peroxidation Cerebral Infarction i.v. Small molecule
Preclinical · Showed more potent 4-hydroxynonenal - quenching activity compared with carnosine or histidine hydrazide (HH) at 30min incubation.
· GEM119 ( ip administration) rescued the hippocampal CA1 cell death of transient cerebral ischemia model of Mongolian gerbil whereas HH did not.
問合せ